NSE ScannerMedical Devices & Supplies · Medical Specialties · NSE: POLYMED · data 2026-10-31
Poly Medicure Limited
In plain words
Price: 30.8% below its 52-week high of ₹2,094.3.
Delivery: 52.4% of traded shares were kept for delivery over the last 10 sessions, against 48.3% over the last 60.
A description of the data, not a recommendation.
Key figures
Growth
| Revenue (last 12 months) | ₹1,997 cr |
| Net profit (last 12 months) | ₹315 cr |
| Sales growth, 3 years (yearly) | 18.8% |
| Profit growth, 3 years (yearly) | 21.6% |
At a glance
Promoters 62.4% (unchanged in a year), pledged 0.0%, institutions 21.3%.
P/E 46.7, dividend yield 0.2%. Price relative to earnings and book value (low is cheaper, not better).
ROE 11.0%, ROCE 10.9%, operating margin 16.7%: how much profit it earns on the money it uses.
Debt/equity 0.11, Profit growth 21.6% and sales growth 18.8% a year over 3 years.
Ratings use fixed thresholds on the latest reported figures. They describe the numbers and are not a recommendation.
Strengths and limitations
- Profit grew 21.6% a year over 3 years.
None flagged by these rules.
Picked automatically from the latest reported figures with fixed rules; check the company's filings before relying on them.
Smart-money activity
19/100 · Weak over the last ~60 sessions, data 2026-10-30
- Delivery vs usual 7/30: Delivery 53.8% over the last 20 sessions vs 42.3% in the 40 before (1.27x); shares delivered per day 0.59x usual; 0 delivery-spike days (3x usual shares delivered, 40%+ delivery) in the last 20 sessions.
- Bulk/block deals 0/20: No bulk or block deals in the last 90 days.
- Insider / SAST buys 0/15: No insider buy or SAST acquisition filings in the last 90 days. Insider sells are not collected by the site, so only buy filings count.
- Mutual fund holding 7/15: 3 schemes hold it, about ₹201 cr in all (as of 2026-09-30). Latest monthly portfolios only (top 60 holdings per scheme); month-on-month change is not stored.
- Accumulation evidence 0/15: No accumulation evidence row (only saved-scan stocks have one; 0 points).
- Promoter pledges 5/5: No promoter pledge filings in 90 days.
A description of recorded activity (delivery, deals, insider buys, fund holding, pledges), not a recommendation. Today's most active stocks.
Story so far
● Dividend
- 28 Aug 26Dividend Dividend ₹3.5 (ex-date) +2.7% next session
- 18 Sept 25Dividend Dividend ₹3.5 (ex-date) 0.0% next session
From official exchange filings and NSE data. How the price moved after an event describes the past, not what comes next.
Shareholding trend
| Holder | Sept 2026 | Jun 2026 | Mar 2026 | Dec 2025 |
|---|---|---|---|---|
| Promoters | 62.42% | 62.42% | 62.42% | 62.42% |
| Foreign institutions (FII) | 5.35% | 5.57% | 5.91% | 9.40% |
| Domestic institutions (DII) | 15.90% | 16.08% | 15.59% | 13.84% |
| Mutual funds | 9.77% | 9.61% | 8.84% | 8.14% |
| Retail investors | 7.71% | 7.34% | 6.93% | 5.81% |
| Number of shareholders | 74,153 | 73,643 | 73,414 | 67,750 |
Common questions
How much do promoters hold in Poly Medicure Limited?
Promoters held 62.42% of Poly Medicure Limited at the end of Sept 2026, with 0.00% of promoter shares pledged.
Is Poly Medicure Limited debt-free?
Its latest reported debt-to-equity ratio is 0.11.
What is Poly Medicure Limited's P/E ratio?
About 46.7, based on the last 12 months' earnings and a price of ₹1,449.5 (data 2026-10-31).
What is the 52-week high and low of Poly Medicure Limited?
The 52-week high is ₹2,094.3 and the 52-week low is ₹1,182.
Mutual funds holding Poly Medicure Limited
From the monthly portfolios of the fund houses the site reads, as of 2026-09-30. 3 schemes holding about ₹201 cr; funds that hold it outside their top holdings may not be listed.
| Scheme | Fund house | % of fund | Value |
|---|---|---|---|
| SBI Healthcare Opportunities Fund | SBI Mutual Fund | 1.82% | ₹107 cr |
| SBI MNC Fund | SBI Mutual Fund | 1.47% | ₹94 cr |
| Mirae Asset Nifty 500 Healthcare ETF | Mirae Asset Mutual Fund | 0.47% | ₹0 cr |
Compared with similar companies
| Company | Price | Market cap | P/E | P/B | ROE | ROCE | Debt/eq. | 1-yr return |
|---|---|---|---|---|---|---|---|---|
| Poly Medicure Limited | ₹1,449.5 | ₹14,676 cr | 46.7 | — | 11% | 10.9% | 0.11 | -26.5% |
| Lenskart Solutions Limited | ₹678.2 | ₹1,17,960 cr | 179 | — | 6.7% | 7.8% | 0.35 | +68.7% |
| Molbio Diagnostics Limited | ₹1,274 | ₹14,689 cr | — | — | 13.8% | 19.2% | 0.3 | +57.9% |
| Standard Engineering Technology Ltd | ₹395.85 | ₹7,885 cr | 92.3 | — | 10.7% | 13.3% | 0.1 | +115.7% |
| Sahajanand Medical Technologies Limited | ₹462.7 | ₹4,675 cr | — | — | — | — | — | +24.7% |
| Virtuoso Optoelectronics Limited | ₹460.2 | ₹1,575 cr | 83.5 | — | 4.3% | -3.5% | 0.84 | +2.3% |
Compare POLYMED with LENSKART in detail →
The full analysis has the price chart, every quarterly result with YoY/QoQ growth, the balance sheet and cash flow with an accounting red-flag check, shareholding quarter by quarter with big investors, news, filings and bulk/block deals.
Open POLYMED in NSE Scanner →